- ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease
This study is testing a new pneumonia vaccine called V116. It's for adults aged 18-64 who are at higher risk of getting pneumonia. We want to see how safe it is, if people can tolerate it well, and how good it is at fighting off the infection compared to existing vaccines.
Poland - authorisedHuman Pharmacology (Phase I)- First administration to humans
A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.
This study is testing a new vaccine to protect against serious lung and blood infections caused by pneumococcal bacteria. It's for healthy adults aged 18-50 and will check if the vaccine is safe and how well the body responds to it.
Belgium